Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.

Williams M, Cheng YY, Kirschner MB, Sarun KH, Schelch K, Winata P, McCaughan B, Kao S, Van Zandwijk N, Reid G.

Oncotarget. 2019 Jun 25;10(41):4125-4138. doi: 10.18632/oncotarget.27010. eCollection 2019 Jun 25.

2.

Patterns of care and survival of older patients with malignant pleural mesothelioma.

Linton A, Blinman P, Kao S, van Zandwijk N.

J Geriatr Oncol. 2019 Jul;10(4):573-576. doi: 10.1016/j.jgo.2019.02.013. Epub 2019 Mar 24.

PMID:
30917938
3.

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

Jiang T, Su C, Ren S, Cappuzzo F, Rocco G, Palmer JD, van Zandwijk N, Blackhall F, Le X, Pennell NA, Zhou C; written on behalf of the AME Lung Cancer Collaborative Group.

J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61. Review.

4.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
5.

Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)".

van Zandwijk N, McDiarmid J, Brahmbhatt H, Reid G.

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S60-S61. doi: 10.21037/tlcr.2018.01.11. No abstract available.

6.

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.

Linton A, Cheng YY, Griggs K, Schedlich L, Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC, Klebe S, van Zandwijk N, Reid G.

Br J Cancer. 2018 Mar 20;118(6):e13. doi: 10.1038/bjc.2018.3. Epub 2018 Feb 13.

7.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C.

ESMO Open. 2017 Jan 13;1(6):e000118. doi: 10.1136/esmoopen-2016-000118. eCollection 2016.

8.

The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection.

Winata P, Williams M, McGowan E, Nassif N, van Zandwijk N, Reid G.

BMC Res Notes. 2017 Nov 17;10(1):600. doi: 10.1186/s13104-017-2930-0.

9.

Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.

Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G.

J Thorac Oncol. 2018 Feb;13(2):258-272. doi: 10.1016/j.jtho.2017.10.016. Epub 2017 Nov 4.

10.

A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.

Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G.

Mol Oncol. 2018 Jan;12(1):58-73. doi: 10.1002/1878-0261.12150. Epub 2017 Nov 18.

11.

Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies.

Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED.

J Thorac Oncol. 2017 Dec;12(12):1755-1765. doi: 10.1016/j.jtho.2017.09.1956. Epub 2017 Sep 27. Review.

12.

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.

Lancet Oncol. 2017 Oct;18(10):1386-1396. doi: 10.1016/S1470-2045(17)30621-6. Epub 2017 Sep 1.

PMID:
28870611
13.

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.

Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.

J Thorac Oncol. 2017 Sep;12(9):1421-1433. doi: 10.1016/j.jtho.2017.05.024. Epub 2017 Jun 16. Erratum in: J Thorac Oncol. 2018 Apr;13(4):587.

14.

Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.

Linton A, Soeberg M, Broome R, Kao S, van Zandwijk N.

Respirology. 2017 Jul;22(5):978-985. doi: 10.1111/resp.12981. Epub 2017 Jan 31.

PMID:
28139858
15.

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E.

J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. Review.

16.

Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends.

Soeberg MJ, Leigh J, van Zandwijk N.

J Toxicol Environ Health B Crit Rev. 2016;19(5-6):173-189. Review.

PMID:
27705544
17.

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.

Lin RC, Kirschner MB, Cheng YY, van Zandwijk N, Reid G.

Genom Data. 2016 Jun 20;9:44-9. doi: 10.1016/j.gdata.2016.06.009. eCollection 2016 Sep.

18.

Estimating the incidence of malignant mesothelioma in Vietnam: a pilot descriptive cancer registration study.

Soeberg MJ, Luong MA, Tran VT, Tran AT, Nguyen TT, Bui D, Nguyen TH, Takahashi K, van Zandwijk N.

Int J Occup Environ Health. 2016 Apr;22(2):167-72. doi: 10.1080/10773525.2016.1151604. Epub 2016 Jul 8.

19.

Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.

Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B.

Eur J Cancer. 2016 Aug;63:64-73. doi: 10.1016/j.ejca.2016.04.018. Epub 2016 Jun 8.

PMID:
27288871
20.

KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.

Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G.

Mol Cancer. 2016 Jun 1;15(1):44. doi: 10.1186/s12943-016-0529-z.

21.

Update in lung cancer: epilogue to a modern review series.

Fong KM, van Zandwijk N.

Respirology. 2016 Jul;21(5):789-90. doi: 10.1111/resp.12809. Epub 2016 May 30. No abstract available.

22.

Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.

Reid G, Kao SC, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, Boyer M, van Zandwijk N.

Epigenomics. 2016 Aug;8(8):1079-85. doi: 10.2217/epi-2016-0035. Epub 2016 May 17. Review.

23.

Incidence of malignant mesothelioma in New Zealand and Australia: a global snapshot.

Soberg MJ, van Zandwijk N.

N Z Med J. 2015 Dec 18;128(1427):68-71. No abstract available.

PMID:
26914008
24.

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.

Kao SC, Kirschner MB, Cooper WA, Tran T, Burgers S, Wright C, Korse T, van den Broek D, Edelman J, Vallely M, McCaughan B, Pavlakis N, Clarke S, Molloy MP, van Zandwijk N, Reid G.

Br J Cancer. 2016 Mar 1;114(5):524-31. doi: 10.1038/bjc.2015.470. Epub 2016 Feb 18.

25.

Using a multidisciplinary approach to combat the burden of asbestos-related disease.

van Zandwijk N, Soeberg M, Reid G.

Med J Aust. 2016 Feb 1;204(2):52. No abstract available.

PMID:
26821095
26.

Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.

Soeberg MJ, Leigh J, Driscoll T, Armstrong B, Young JM, van Zandwijk N.

Occup Environ Med. 2016 Mar;73(3):187-94. doi: 10.1136/oemed-2015-103309. Epub 2016 Jan 22.

PMID:
26800709
27.

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009.

Soeberg MJ, Creighton N, Currow DC, Young JM, van Zandwijk N.

Aust N Z J Public Health. 2016 Jun;40(3):255-62. doi: 10.1111/1753-6405.12503. Epub 2015 Dec 29.

PMID:
26713662
28.

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, Edelman JJ, Kao SC, Hyland R, Dong Y, László V, Klikovits T, Vallely MP, Grusch M, Hegedus B, Dome B, Klepetko W, van Zandwijk N, Klebe S, Reid G.

Br J Cancer. 2015 Sep 15;113(6):963-9. doi: 10.1038/bjc.2015.286. Epub 2015 Aug 11.

29.

miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.

Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJ, Vallely MP, McCaughan BC, Cooper W, Klebe S, Lin RC, Brahmbhatt H, MacDiarmid J, van Zandwijk N, Reid G.

Oncotarget. 2015 Sep 15;6(27):23480-95.

30.

A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma.

Kao SC, Fulham M, Wong K, Cooper W, Brahmbhatt H, MacDiarmid J, Pattison S, Sagong JO, Huynh Y, Leslie F, Pavlakis N, Clarke S, Boyer M, Reid G, van Zandwijk N.

Am J Respir Crit Care Med. 2015 Jun 15;191(12):1467-9. doi: 10.1164/rccm.201503-0461LE. No abstract available.

PMID:
26075427
31.

Update in lung cancer: prologue to a modern review series.

van Zandwijk N, Fong KM.

Respirology. 2015 Feb;20(2):183-4. doi: 10.1111/resp.12457. No abstract available.

32.

MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.

Kirschner MB, Cheng YY, Armstrong NJ, Lin RC, Kao SC, Linton A, Klebe S, McCaughan BC, van Zandwijk N, Reid G.

Mol Oncol. 2015 Mar;9(3):715-26. doi: 10.1016/j.molonc.2014.11.007. Epub 2014 Dec 2.

33.

Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.

Kao SC, van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W.

Asia Pac J Clin Oncol. 2015 Mar;11(1):85-92. doi: 10.1111/ajco.12306. Epub 2014 Nov 10.

PMID:
25382807
34.

Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.

Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N.

Br J Cancer. 2014 Oct 28;111(9):1860-9. doi: 10.1038/bjc.2014.478. Epub 2014 Sep 4.

35.

Comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'.

Kao SC, van Zandwijk N, Clarke S.

Br J Cancer. 2014 Dec 9;111(12):2376. doi: 10.1038/bjc.2014.185. Epub 2014 Apr 8. No abstract available.

36.

Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.

Cheng NC, van Zandwijk N, Reid G.

PLoS One. 2014 Mar 3;9(3):e90374. doi: 10.1371/journal.pone.0090374. eCollection 2014.

37.

ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.

Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJ, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G.

J Thorac Oncol. 2013 Oct;8(10):1317-28. doi: 10.1097/JTO.0b013e3182a0840a.

38.

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, Currow D, Schofield P, Nick Pavlakis BI, McLean J, Marshall H, Leong S, Keena V, Penman A.

J Thorac Dis. 2013 Dec;5(6):E254-307. doi: 10.3978/j.issn.2072-1439.2013.11.28. Review. No abstract available.

39.

Clinical practice guidelines for malignant pleural mesothelioma.

van Zandwijk N.

J Thorac Dis. 2013 Dec;5(6):724-5. doi: 10.3978/j.issn.2072-1439.2013.12.50. No abstract available.

40.

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.

Linton A, Cheng YY, Griggs K, Schedlich L, Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC, Klebe S, van Zandwijk N, Reid G.

Br J Cancer. 2014 Jan 21;110(2):510-9. doi: 10.1038/bjc.2013.731. Epub 2013 Dec 10. Erratum in: Br J Cancer. 2018 Feb 13;:.

41.

Does miR-1 play a role in malignant pleural mesothelioma development and progression?

Wright CM, Kirschner MB, van Zandwijk N, Reid G.

Chest. 2013 Dec;144(6):1971. doi: 10.1378/chest.13-1657. No abstract available.

PMID:
24297134
42.

Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.

Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N.

Ann Oncol. 2013 Dec;24(12):3128-35. doi: 10.1093/annonc/mdt412. Epub 2013 Oct 22.

PMID:
24148817
43.

Inflammation in malignant mesothelioma - friend or foe?

Linton A, van Zandwijk N, Reid G, Clarke S, Cao C, Kao S.

Ann Cardiothorac Surg. 2012 Nov;1(4):516-22. doi: 10.3978/j.issn.2225-319X.2012.10.02. No abstract available.

44.

Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

van Zandwijk N, Reid G, Linton A, Kao S.

Ann Cardiothorac Surg. 2012 Nov;1(4):481-6. doi: 10.3978/j.issn.2225-319X.2012.10.01. No abstract available.

45.

Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).

Wright CM, Kirschner MB, Cheng YY, O'Byrne KJ, Gray SG, Schelch K, Hoda MA, Klebe S, McCaughan B, van Zandwijk N, Reid G.

PLoS One. 2013 Aug 19;8(8):e70940. doi: 10.1371/journal.pone.0070940. eCollection 2013.

46.

Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.

Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S.

J Clin Pathol. 2013 Oct;66(10):854-61. doi: 10.1136/jclinpath-2013-201609. Epub 2013 Jul 6. Review.

PMID:
23833051
47.

Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.

Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S.

J Clin Pathol. 2013 Oct;66(10):847-53. doi: 10.1136/jclinpath-2012-201303. Epub 2013 Jun 27. Review.

PMID:
23814259
48.

The Impact of Hemolysis on Cell-Free microRNA Biomarkers.

Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G.

Front Genet. 2013 May 24;4:94. doi: 10.3389/fgene.2013.00094. eCollection 2013.

49.

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ, Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR, Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, Bernards R.

J Pathol. 2013 Jul;230(3):270-6. doi: 10.1002/path.4209.

PMID:
23661334
50.

Cell-free microRNAs: potential biomarkers in need of standardized reporting.

Kirschner MB, van Zandwijk N, Reid G.

Front Genet. 2013 Apr 19;4:56. doi: 10.3389/fgene.2013.00056. eCollection 2013.

Supplemental Content

Loading ...
Support Center